FDA Updates FDALabel Database, Providing Access to Over 150,000 Drug Labels
The Role and Latest Updates of FDA's FDALabel from the National Center for Toxicological Research
The FDALabel, developed by the National Center for Toxicological Research (NCTR) under the U.S. Food and Drug Administration (FDA), is a web-based bioinformatics application that allows users to search through over 155,000 drug labeling documents. The recently released Version 2.10 (released in August 2025) features enhanced search capabilities and a more user-friendly interface. This database is updated monthly with Structured Product Labeling (SPL) archive data, ensuring that it contains the latest information. Researchers can use this tool to access a vast amount of regulatory data in real-time, including prescription drugs for humans and animals, over-the-counter (OTC) medications, and biological products.
Addressing Information Asymmetry Through Detailed Analysis
This system provides powerful filtering capabilities, allowing users to search for specific sections within a product's description, such as 'Adverse Reactions,' 'Indications and Usage,' or 'Drug Interactions,' going beyond simple keyword searches. This significantly reduces the information asymmetry that pharmaceutical companies face when collecting safety warning or indication information for competitor products during the new drug development process. In particular, it has become an essential research infrastructure for clinical researchers, as it allows them to extract large amounts of data on drug-induced liver injury (DILI) or serious adverse events and export it to Excel.
Competition and Differentiation from Other Regulatory Databases
FDALabel competes with and complements existing systems such as the National Library of Medicine (NLM)'s DailyMed and Drugs@FDA. While DailyMed focuses on displaying the latest labels submitted by manufacturers, FDALabel specializes in regulatory science research, allowing users to compare the labels of multiple drugs at once. Unlike Drugs@FDA, which focuses on approval history and review reports, FDALabel is more useful for tracing back information on the mechanism of action (MOA) or target molecule within actual prescription data.
Value in Reducing New Drug R&D Costs and Enhancing Safety
In the global pharmaceutical research and development (R&D) market, which amounts to trillions of dollars annually, thorough pharmacovigilance and toxicity analysis must be conducted from the early stages to reduce the failure rate of drug development. FDALabel helps prevent clinical failure risks and costs of hundreds of millions of dollars by analyzing the adverse reaction patterns of existing drugs in the early exploratory stages or during the design of Phase 1/2/3 clinical trials. It also has public value by combining with post-marketing surveillance (PMS) data to strengthen the safety profile of drugs and provide more precise dosage guidelines to patients.
FDALabel Version 2.10 provides free access to over 150,000 drug label information, enabling pharmaceutical companies to proactively screen for toxicity risks and adverse event data during the early stages of new drug development and the design of Phase 1/2/3 clinical trials, thereby increasing R&D efficiency. This has short-term implications in reducing information acquisition costs and clinical failure rates in the global new drug R&D market, which is estimated at approximately $150 billion annually. Researchers and regulatory science professionals can leverage its powerful section search and data filtering capabilities, free of charge, to quantitatively analyze the adverse reaction rates of competing drugs, compared to expensive commercial platforms such as Cortellis. In the medium to long term, it will provide refined labeling big data for artificial intelligence-based drug repurposing research, shortening the drug candidate discovery period and accelerating value creation in the pharmaceutical industry.
Source: FDA Drug Approvals (rss)